RIL
KROS icon

Rothschild Investment LLC’s Keros Therapeutics KROS Stock Holding History

Rothschild Investment LLC’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.54K Buy
230
+66
+40% +$1.02K ﹤0.01% 2436
2025
Q4 		$3.34K Sell
164
-11
-6% -$193 ﹤0.01% 2103
2025
Q3 		$2.77K Hold
175
– – ﹤0.01% 2020
2025
Q2 		$2.34K Sell
175
-5
-3% -$68 ﹤0.01% 1967
2025
Q1 		$1.83K Buy
180
+145
+414% +$1.68K ﹤0.01% 1949
2024
Q4 		$554 Sell
35
-5
-13% -$260 ﹤0.01% 2491
2024
Q3 		$2.32K Buy
40
+25
+167% +$1.24K ﹤0.01% 1646
2024
Q2 		$686 Buy
15
+10
+200% +$537 ﹤0.01% 1851
2024
Q1 		$331 Buy
+5
New +$296 ﹤0.01% 1512

Other funds holding KROS

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return